Table 3.

Univariate and multivariate analysis of pyrazinamide resistance by the Wayne assay in subjects in a TB cohort study in Lima.

Variable	Unadjusted OR (95% CI)*	Adjusted OR (95% CI)*
Age	0.99 (0.99–1.00)	1.00 (0.99–1.02)
Sex
Male	Reference	Reference
Female	0.80 (0.59–1.07)	0.78 (0.53–1.16)
Incarceration in the past 5 years (n=3,242)
No	Reference
Yes	1.06 (0.58–1.94)	N/A
Type of housing (n=3,249)
Standard housing	Reference
Substandard housing	0.83 (0.53–1.29)	N/A
Region
Lima Ciudad	Reference	Reference
Lima Este	2.17 (1.54–3.07)	1.34 (0.82–2.20)
Previous treatment (n=3,268)
No	Reference	Reference
Yes	2.80 (2.09–3.75)	1.38 (0.92–2.08)
Cavitary disease (n=3,221)
No	Reference	Reference
Yes	0.76 (0.55–1.04)	0.61 (0.40–0.93)
MDR-TB
No	Reference	Reference
Yes	108.0 (69.1–168.8)	86.0 (54.0–136.9)
LAM lineage (n=3,247)
No	Reference	Reference
Yes	5.46 (4.06–7.34)	3.40 (2.33–4.96)

CI=confidence interval; MDR-TB=multidrug-resistant tuberculosis; PZA=pyrazinamide; OR=odds ratio.

^*Boldface indicates P < 0.05. The multivariate model uses n=3,187 (97.3%) observations with complete data.